There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

A MOTHER has revealed that she has lost 10 and a half stone after using Mounjaro.  Becca Banks, a mum-of-one from the UK, ...

Semaglutide, the diabetes and weight loss drug that’s commonly known as Ozempic, can help patients of peripheral artery ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...